Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
12 2021
Historique:
received: 05 01 2021
revised: 04 03 2021
accepted: 17 03 2021
pubmed: 10 10 2021
medline: 15 12 2021
entrez: 9 10 2021
Statut: ppublish

Résumé

Migrant populations are one of several underimmunised groups in the EU or European Economic Area (EU/EEA), yet little is known about their involvement in outbreaks of vaccine-preventable diseases. This information is vital to develop targeted strategies to improve the health of diverse migrant communities. We did a systematic review (PROSPERO CRD42019157473; Jan 1, 2000, to May 22, 2020) adhering to PRISMA guidelines, to identify studies on vaccine-preventable disease outbreaks (measles, mumps, rubella, diphtheria, pertussis, polio, hepatitis A, varicella, Neisseria meningitidis, and Haemophilus influenzae) involving migrants residing in the EU/EEA and Switzerland. We identified 45 studies, reporting on 47 distinct vaccine-preventable disease outbreaks across 13 countries. Most reported outbreaks involving migrants were of measles (n=24; 6496 cases), followed by varicella (n=11; 505 cases), hepatitis A (n=7; 1356 cases), rubella (n=3; 487 cases), and mumps (n=2; 293 cases). 19 (40%) outbreaks, predominantly varicella and measles, were reported in temporary refugee camps or shelters. Of 11 varicella outbreaks, nine (82%) were associated with adult migrants. Half of measles outbreaks (n=11) were associated with migrants from eastern European countries. In conclusion, migrants are involved in vaccine-preventable disease outbreaks in Europe, with adult and child refugees residing in shelters or temporary camps at particular risk, alongside specific nationality groups. Vulnerability varies by disease, setting, and demographics, highlighting the importance of tailoring catch-up vaccination interventions to specific groups in order to meet regional and global vaccination targets as recommended by the new Immunisation Agenda 2030 framework for action. A better understanding of vaccine access and intent in migrant groups and a greater focus on co-designing interventions is urgently needed, with direct implications for COVID-19 vaccine delivery.

Identifiants

pubmed: 34626552
pii: S1473-3099(21)00193-6
doi: 10.1016/S1473-3099(21)00193-6
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e387-e398

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests SH is a freelance Senior Editor for The Lancet Infectious Diseases and other Lancet journals. All other authors declare no competing interests.

Auteurs

Anna Deal (A)

The Migrant Health Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK; Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.

Rae Halliday (R)

The Migrant Health Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK.

Alison F Crawshaw (AF)

The Migrant Health Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK.

Sally E Hayward (SE)

The Migrant Health Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK; Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.

Amelia Burnard (A)

The Migrant Health Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK.

Kieran Rustage (K)

The Migrant Health Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK.

Jessica Carter (J)

The Migrant Health Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK.

Anushka Mehrotra (A)

One Health Lewisham, London, UK.

Felicity Knights (F)

The Migrant Health Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK.

Ines Campos-Matos (I)

Public Health England, London, UK; UCL Collaborative Centre for Inclusion Health, University College London, London, UK.

Azeem Majeed (A)

Department of Primary Care & Public Health, Imperial College London, London, UK.

Jon S Friedland (JS)

The Migrant Health Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK.

Michael Edelstein (M)

Faculty of Medicine, Bar-Ilan University, Safed, Israel.

Sandra Mounier-Jack (S)

Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.

Sally Hargreaves (S)

The Migrant Health Research Group, Institute for Infection and Immunity, St George's, University of London, London, UK. Electronic address: s.hargreaves@sgul.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH